
Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults
Key Points
Key Points
Success of these devices and technologies is directly linked to the level to which people are educated, capable, and willing to use them.
This guideline attempts to assess all available data on existing and emerging technologies and procedures for improving glucose control for patients with diabetes.
Treatment
Treatment
Insulin Pump Therapy Without Sensor Augmentation
Insulin Pump Therapy in Type 2 Diabetes Mellitus
Insulin Pump Use in the Hospital
Selection of Candidates for Insulin Pump Therapy
Use of Bolus Calculators in Insulin Pump Therapy
Real-Time Continuous Glucose Monitors in Adult Outpatients
Use of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Mellitus
Education and Training on the Use of Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring
Table 1. CSII—Considerations for Education and Training
Patient |
---|
Collaborate with health care professional (HCP) overseeing CSII use and/or the multidisciplinary diabetes team by returning for follow-up. Participate in using data management resources to make adjustments to therapy and evaluate self-care behaviors. |
Provider |
Provide education as indicated to address deficiencies or when upgrading to new technology. |
Assess CSII use and evaluate for the loss of ability to operate insulin pump due to cognitive, physical, or age-related changes; changes in insurance coverage; or changes in the healthcare provider managing CSII use. |
Time periods to assess patient self-care behaviors and knowledge before initiating CSII, assess: |
Glucose monitoring via self-monitoring blood glucose (SMBG) frequency, and/or CGM use defined by HCP to meet individualized glycemic goals. |
Carbohydrate counting or another method of mealtime bolus determination. |
Ability to operate CSII and make setting changes due to factors such as dexterity, vision impairment, mental health, or cognition—independently or with assistance from a designated care provider. |
Infusion site health and selection. |
DKA prevention and treatment. |
Hypoglycemia—prevention, detection, and treatment. |
Emergency supplies. |
If using bolus calculator, assess these settings: insulin-to-carbohydrate ratio, insulin sensitivity factor, glucose targets, and active insulin time. |
Annually and/or when upgrading to a new CSII device, re-assess: |
Glucose monitoring via SMBG frequency and/or CGM use defined by HCP to meet individualized glycemic goals. |
Basal settings via basal rate testing across different time periods, adjust as indicated. |
Bolus calculator settings, if using feature, adjust as indicated. |
Infusion sites and type of infusion set, adjust as indicated. |
Ability to troubleshoot insulin pump malfunction. |
DKA prevention and treatment. |
Hypoglycemia prevention, detection, and treatment. |
Emergency supplies. |
Back-up plan for use of injected insulin should pump fail. |
When discontinuing CSII or transitioning to MDI, re-assess: |
Glucose monitoring via SMBG frequency and/or CGM use defined by HCP to meet individualized glycemic goals. New insulin plan for MDI. |
Table 2. RT-CGM Technology—Considerations for Education and Training for Personal Use
Patient |
---|
Collaborate with HCP overseeing RT-CGM use and/or the multidisciplinary diabetes team by returning for follow-up. |
Participate in use of data management resources to make adjustments to therapy and evaluate self-care behaviors. |
Provider |
Provide education as indicated to address deficiencies or when upgrading to new CGM technology. |
On an ongoing basis, assess CGM use and evaluate for the loss of ability to operate CGM system due to: cognitive, physical, or age-related changes; changes in insurance coverage; or changes in the healthcare provider managing CGM use. |
Time periods to assess patient self-care behaviors and knowledge |
Before initiating RT-CGM, assess: |
Patient understanding that CGM does not replace SMBG. |
Factors and self-care behaviors that may influence success with CGM. |
When initiating RT-CGM, assess: |
Knowledge of CGM system components—receiver, sensor, and transmitter. |
Understanding of how CGM data differ from SMBG data. |
Use of trend information based on changing glucose levels to adjust insulin doses. |
Use of SMBG to calibrate CGM system. |
Site selection and care. |
Alarms (Check that alarms are set in a fashion to optimize patient benefit and minimize alarm fatigue. The initial focus is often on low alerts and falling blood glucose alarms. High alerts can be turned off or set well above target at first if patient is consistently high and doesn’t benefit from high alerts.) |
Annually and/or when upgrading technology (for ongoing RT-CGM use), re-assess: |
Ability to make insulin adjustment based on trend information. |
Use of SMBG to calibrate. |
Sensor site health and care. |
Table 3. Suggested Health Care Provider Resources to Support the Safe and Effective Use of CSII and RT-CGM
Clinicians should implement a formalized educational plan for the initiation and long-term support of CSII and RT-CGM that is established by the practice setting. Clinicians should communicate education plans to potential candidates and individuals new to the practice setting. |
Clinics should have a designated multidisciplinary diabetes team to evaluate potential candidates, initiate therapy and education, and to support long-term CSII and RT-CGM use that is part of the practice setting. Alternatively, a sole practitioner may also provide medical care and CSII education supported by other healthcare professionals or industry consultants as indicated. CSII and RT-CGM diabetes care team members could include the following health care providers: endocrinologist, advanced practice registered nurse, physician’s assistant, primary care provider, certified diabetes educator, registered dietitian with expertise in diabetes medical nutrition therapy, and mental health/behavioral therapists. |
The clinical support staff or patient should know how to download data from glucose meters, insulin pumps, and RT-CGMs, and they should download data before an appointment in order to review data via print format, online secure patient pump portal, or the patient’s electronic health record. |
Designated staff members (diabetes educators, medical assistants, or patient service representatives) should be available to help clinics obtain prior authorizations, schedule peer-to-peer reviews, submit supporting documents for determining coverage, answer insurance and distributor/third party vendor queries for additional documentation, and issue letters of support and/or appeal if therapy is declined. |
Toolkit Resource Section
Toolkit Resource Section
Additional Guidance from Professional Societies and Organizations
Excerpts from 2021 American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus
Insulin Delivery Technologies
Q2.6 Who would benefit from the use of connected pens?
Q2.7 Who would benefit from the use of an insulin pump without continuous glucose monitoring?
Q2.8 Who would benefit from the use of an insulin pump with continuous glucose monitoring (separate devices or sensor-augmented pump)?
Q2.9 Who would benefit from the use of more advanced insulin pump technologies: low-glucose suspend, predictive low-glucose suspend, and hybrid closed loop?
ADA 2022 Standards of Care - Highlight of New Recommendations:
Diabetes Technology Introduction
- The type(s) and selection of devices should be individualized based on a person’s specific needs, desires, skill level, and availability of devices. In the setting of an individual whose diabetes is partially or wholly managed by someone else (e.g., a young child or a person with cognitive impairment), the caregiver’s skills and desires are integral to the decision-making process. E
- When prescribing a device, ensure that people with diabetes/caregivers receive initial and ongoing education and training, either in-person or remotely, and regular evaluation of technique, results, and their ability to use data, including uploading/sharing data (if applicable), to adjust therapy. C
- People who have been using continuous glucose monitoring, continuous subcutaneous insulin infusion, and/or automated insulin delivery for diabetes management should have continued access across third-party payers. E
- Students must be supported at school in the use of diabetes technology including continuous subcutaneous insulin infusion, connected insulin pens, and automated insulin delivery systems as prescribed by their diabetes care team. E
- Initiation of continuous glucose monitoring, continuous subcutaneous insulin infusion, and/or automated insulin delivery early in the treatment of diabetes can be beneficial depending on a person’s/caregiver’s needs and preferences. C
Insulin Pumps and Automated Insulin Delivery Systems
- Automated insulin delivery systems should be offered or diabetes management to youth and adults with type 1 diabetes A and other types of insulin-deficient diabetes E who are capable of using the device safely (either by themselves or with a caregiver). The choice of device should be made based on patient circumstances, desires, and needs.
- Insulin pump therapy alone with or without sensor-augmented low glucose suspend should be offered for diabetes management to youth and adults on multiple daily injections with type 1 diabetes A or other types of insulin-deficient diabetes E who are capable of using the device safely (either by themselves or with a caregiver) and are not able to use/interested in an automated insulin delivery system. The choice of device should be made based on patient circumstances, desires, and needs. A
- Insulin pump therapy can be offered for diabetes management to youth and adults on multiple daily injections with type 2 diabetes who are capable of using the device safely (either by themselves or with a caregiver). The choice of device should be made based on patient circumstances, desires, and needs. A
- Individuals with diabetes who have been successfully using continuous subcutaneous insulin infusion should have continued access across third-party payers. E
ADA evidence-grading system for “Standards of Medical Care in Diabetes”
Level of evidence | Description |
---|---|
A | Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including |
Evidence from a well-conducted multicenter trial | |
Evidence from a meta-analysis that incorporated quality ratings in the analysis | |
Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Centre for Evidence-Based Medicine at the University of Oxford | |
Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including | |
Evidence from a well-conducted trial at one or more institutions | |
Evidence from a meta-analysis that incorporated quality ratings in the analysis | |
B | Supportive evidence from well-conducted cohort studies |
Evidence from a well-conducted prospective cohort study or registry | |
Evidence from a well-conducted meta-analysis of cohort studies | |
Supportive evidence from a well-conducted case-control study | |
C | Supportive evidence from poorly controlled or uncontrolled studies |
Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results | |
Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls) | |
Evidence from case series or case reports | |
Conflicting evidence with the weight of evidence supporting the recommendation | |
E | Expert consensus or clinical experience |
Consensus Statement by the American Association of Endocrinologists / American College of Endocrinology - Insulin Pump Management Task Force
- Based on currently available data, CSII is justified for basal-bolus insulin therapy in patients with type 1 diabetes mellitus (T1DM)
- Only providers whose practice can assume full responsibility for a comprehensive pump management program should offer this technology
- Appropriate patient selection is necessary and must include a thorough assessment of the patient’s knowledge of diabetes management principles
- The ideal CSII candidate is:
- A patient with T1DM or intensively managed insulin-dependent T2DM
- Currently performing ≥4 insulin injections and ≥4 self-monitored blood glucose (SMBG) measurements daily
- Motivated to achieve optimal blood glucose control
- Willing and able to carry out the tasks that are required to use this complex and time-consuming therapy safely and effectivel
- Willing to maintain frequent contact with their health care team
- Adult patients
- At CSII initiation, the patient should have daily contact with the pump trainer
- A return visit with the endocrinologist/diabetologists/advanced practice nurse is advised within 3 to 7 days of initiation
- Educational consults should be scheduled weekly or biweekly at first, then periodically as needed
- Specialist follow-up visits should be scheduled at least monthly until the pump regimen is stabilized, then at least once every 3 months
- Pediatric patients
- An international consensus conference of leading pediatric diabetes specialists agreed that CSII was indicated for pediatric patients with:
- Elevated hemoglobin A1c (HbA1c) levels on injection therapy
- Frequent, severe hypoglycemia
- Widely fluctuating glucose levels
- A treatment regimen that compromises lifestyle
- Microvascular complications and/or risk factors for macrovascular complications
- Ideal pediatric candidates are those with motivated families who are committed to monitoring blood glucose ≥4 times/day and have a working understanding of basic diabetes management
- Patient age and duration of diabetes should not be factors in determining the transition from injections to CSII
- An international consensus conference of leading pediatric diabetes specialists agreed that CSII was indicated for pediatric patients with:
- Patient diabetes education and pump training should be implemented by a multidisciplinary team under the direction of an experienced endocrinologist/ diabetologist
- Patients must be educated on the meaning of pump alarms, particularly those that may signal a potential interruption to insulin delivery
- Patients must be taught to keep backup supplies on hand in the event of a pump or infusion set failure
- Patients/families should undergo periodic retesting of skills to maximize the effectiveness of pump therapy and maintain patient safety
- Patients should have the knowledge and technical ability to make recommended pump setting changes at home
- Patients/families should be trained to handle emergency situations
- Patients should be retrained when switching to a new pump model
- All patients should have periodic re-education and retraining to address knowledge gaps, as well as to troubleshoot any issues with the pump system and glycemic control
- The health care team should periodically re-evaluate whether pump therapy is appropriate for the patient
- Schools and hospitals should be provided with manufacturers’ information describing insulin pump use, along with a contact to answer questions and provide further training
- Providers should have on-call systems available 24 hours/day to handle patient questions; patients should also be periodically reminded of the pump manufacturer’s emergency number
Shared Decision-Making Tool
Factors to Consider When Prescribing CSII:
- Willingness to try device(s) and participate in follow ups
- Adherence
- Activity levels
- Access (Price and Insurance Coverage)
- Ease of use
- Feelings about needles (e.g. needle phobia)
- Comfort with technology
- Trial periods
- Discretion
- And more
Are you willing and able to try an insulin pump?
Have you struggled with engagement with your therapy in the past?
How active is your lifestyle? And is a waterproof device important to you?
Are you able to obtain access to your desired device? (Price and Insurance Coverage):
How important is it to you that the therapy is simple to use?
How do you feel about needles and frequent injections?
How comfortable are you with technology, and is it important for your healthcare team to be able to monitor your numbers regularly?
How important is it to you to have some sort of money back guarantee or trial period?
Is discretion important to you?
Other factors to consider: Is customization important to you? Are good reviews and customer feedback a major factor? Are you looking for a device that is “future proof” with things like software updates? Are you interested in sharing data with other connected devices and receiving personalized insights? Are you looking for something that can help simplify your life?
Comparison Table
Multiple Daily Injections | Tubed Insulin Pump Therapy 1 | Tubeless Insulin Pump Therapy 1 | |
---|---|---|---|
What will you need to carry? |
|
|
|
Where to carry it? |
|
|
|
Considerations |
|
|
|
ILLNESS Most common: BGs rise and sometimes BGs go low |
|
| |
STRESS Most common: BGs rise 1 |
|
| |
ACTIVITY Most common: BGs rise 1 |
|
|
|
VARIABLE SCHEDULES Variable schedules make it a challenge to manage BGs |
|
|
* For Omnipod® Products
1. Bolderman, K. Putting your patients on the pump. 2nd ed. American Diabetes Association. 2013.
Critical Success Factors with Insulin Pump Use
While almost anyone is capable of using insulin pumps, the most important requirement is that the patient and/or the patient’s caregivers are ready and willing to do what it takes to use the pump safely.
A successful user is:
- Responsible
- Knowledgeable about diabetes selfcare
- Desiring for better glycemic control
- Willing to monitor blood sugars as required
- Willing to undergo insulin pump training to safely use the technology
- Understanding that success of insulin pump therapy is reliant on knowledgeable users and interaction with you care team
A successful user will have the opportunity to take advantage of a number of advantages that come with insulin pump therapy, including
- Increased flexibility in lifestyle
- Predictable and precise insulin delivery
- Blood glucose improvements, while reducing the risk of hypoglycemia
- Reducing episodes of severe hypoglycemia
- And more
Additional Information
Automated Insulin Delivery Systems
- Automated insulin delivery systems increase and decrease insulin delivery based on sensor-derived glucose level to begin to approximate physiologic insulin delivery.
- These systems consist of three components: an insulin pump, a continuous glucose sensor, and an algorithm that determines insulin delivery.
- With these systems, insulin delivery can not only be suspended but also increased or decreased based on sensor glucose values.
- While eventually insulin delivery in closed-loop systems may be truly automated, currently meals must be announced.
- A so-called hybrid approach, hybrid closed-loop, has been adopted in first-generation closed-loop systems and requires users to bolus for meals and snacks.
- Multiple studies, using a variety of systems with varying algorithms, pump, and sensors, have been performed in adults and children.
- Evidence suggests such systems may reduce A1C levels and improve time in range. They may lower the risk of exercise-related hypoglycemia and may have psychosocial benefits.
- Use of these systems depends on patient preference and selection of patients (and/or caregivers) who are capable of safely and effectively using the devices.
Clinical benefits of Tubeless Insulin Pump
Tubeless Automated Insulin Delivery System
- In the single-arm, multicenter, prospective study of 240 participants [112 children (age 6–13.9 years) and 128 adults and adolescents (age 14–70 years)] with type 1 diabetes who initiated the Omnipod® 5 AID System demonstrated a reduction in HbA1c after 3 months in children by -0.71% (p < 0.0001) and in adults by -0.38% (p < 0.0001) compared to standard therapy. Time in range improved by 15.6% (3.7 h/day) in children and 9.3 (2.2 h/day) in adults and adolescents (both P < 0.0001). This was accomplished with a reduction in time in hypoglycemia <70 mg/dL among adults: 2.00% to 1.09% [0.46, 1.75], P < 0.0001), while this parameter remained the same in children. There were three severe hypoglycemia events and one diabetic ketoacidosis event. These cases were not related to automated insulin delivery malfunction.[5]
Tubeless Insulin pump
Type 1 Diabetes
HbA1c change:
- Multisite, retrospective study of 873 pediatric, adolescent, and adult patients with type 1 diabetes on multiple daily injections (MDI) and tubed pumps by Layne et al. After 3 months of tubeless insulin pump use, an overall reduction in HbA1c of 0.6% was seen compared to baseline. For MDI patients, HbA1c improved from 8.4% to 7.8%. For previous tubed pump users, HbA1c improved from 8.3% to 7.8% These improvements were seen across all age groups independent of prior treatment. [6]
- Multicenter, retrospective electronic health record–based clinical investigation. 156 adult patients with T1D who had been using either tubed CSII or multiple daily injections (MDI) for diabetes maintenance. Overall, HbA1c reduction was -0.3% following the switch to tubeless CSII, from 8.1% to 7.8% Among patients switching from MDI, the drop was -0.4% (from 8.2 to 7.8). The change was most notable for patients whose baseline A1C reading was 9% or higher. Those patients had a decrease of −1.2%.[7]
Total daily dose change:
- Another important finding in the Layne et al. type 1 diabetes study was the reduction in the total daily dose (TDD) of insulin with tubeless insulin pump use reported for both previous MDI and tubed pump users. There was a 16.4% decrease in TDD of insulin at 3 months for the total population. [6]
Hypoglycemia:
- Layne et al. data showed that the frequency and severity of self-reported hypoglycemia decreased significantly in participants with type 1 diabetes (2.6/ week to 1.6/week). Improvements in hypoglycemia frequency and severity were significant across all age groups independent of prior treatment modality.[6]
Type 2 Diabetes [8]:
- 3,592 Adults with Type 2 diabetes experienced a significant reduction in HbA1c (-1.3%, p<0.0001), Total Daily Dose (-33U, p<0.0001) & self-reported Hypoglycemic Events (-0.5/week, p<0.0001) after only 3 months of Omnipod® use in a retrospective study.
Quality of Life [9]:
- In a survey study by Polonsky and colleagues of more than 1200 adults with type 1 diabetes using the tubeless insulin management system, there were QOL and clinical benefits associated with use of this system. The majority of patients reported positive changes in overall well-being (53.5%), perceived control over diabetes (72.5%), hypoglycemic safety (50.6%), and diabetes distress (69.6%). Improvement in glycemic control was also reported by the majority (64.2%) of respondents with 35.2% reporting a decrease in episodes of severe hypoglycemia. These data are particularly compelling as 44% of respondents had previously used a tubed pump.
References:
- https://www.endocrine.org/clinical-practice-guidelines/diabetes-technology
- https://marlin-prod.literatumonline.com/pb-assets/Health%20Advance/journals/eprac/EPRAC180.pdf
- https://diabetesjournals.org/care/article/45/Supplement_1/S97/138911/7-Diabetes-Technology-Standards-of-Medical-Care-in
- https://www.endocrinepractice.org/article/S1530-891X(20)42190-1/fulltext
- Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. HbA1c was significantly reduced in children by 0.71% (mean ± SD: 7.67 ± 0.95% to 6.99 ± 0.63%, P < 0.0001) and in adults by 0.38% (7.16 ± 0.86% to 6.78 ± 0.68% [55 ± 9.4 mmol/mol to 51 ± 7.4 mmol/mol], P < 0.0001).Mean time 70-180mg/dL as measured by CGM in adults/adolescents and children, ST vs. Omnipod 5: 64.7% vs. 73.9%, P<0.0001; 52.5% vs. 68.0%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM
- J. Layne et al. Journal of Diabetes Science and Technology 2016, Vol. 10(5) 1130–1135. Note that A1C and TDD results could be self-reported or taken from medical records.
- Mehta S, Tinsley L, Kruger D, et al. Improved glycemic control following the transition to tubeless insulin pump therapy in adults with type 1 diabetes. Published by Clinical Diabetes Journal, December 2020. It was a multicenter, retrospective electronic medical record study in the US. 156 adults with type 1 diabetes (≥18 years of age) initiated therapy with Omnipod® System after either MDI (n=99) or CSII with a tubed insulin pump (n=57). The primary endpoint was a change in A1C from the time of transition (baseline) to 12 months following initiation of the tubeless insulin pump. In HbA1c analysis, baseline vs. 12-month follow-up HbA1c values were 8.1% vs 7.8% respectively, p<0.01.
- Carlson, AL et al. Improved Glycemic Control in 3,592 Adults with Type 2 Diabetes Mellitus Initiating a Tubeless Insulin Management System. Diabetes Res Clin Pr; 2021;174,108745: https://doi.org/10.1016/j.diabres.2021.108735 3,592 patients with Type 2 diabetes aged ≥18 years were included in a multisite, retrospective study based in the US. The study evaluated glycemic control and insulin use after three months of Omnipod System and Omnipod DASHR System use, compared to prior treatment with MDI (74%), tubed insulin pumps (15%), and unknown (11%). HbA1c and TDD outcomes were from medical records or self-reported if medical records were not available. HbA1c decreased from (mean ± SD) 9.2 ± 2.0% to 7.9% ± 1.3% overall, p<0.0001; TDD decreased from 103 ± 70U to 71 ± 41U overall, p<0.0001; the self-reported number of HE (<70 mg/dL) per week decreased significantly from 1.2 ± 2.0 to 0.7 ± 1.1 per week , p<0.0001.
- Polonsky WH, et al. Diabetes Technol Ther. 2016 Oct;18(10):664–670
Recommendation Grading
Abbreviations
- CGM: Continuous Glucose Monitoring
- CSII: Continuous Subcutaneous Insulin Infusion
- DKA: Diabetes Ketoacidosis
- HCP: Health Care Professional
- MDI: Multiple Daily Injections
- RT-CGM: Real-time CGM
- SMBG: Self-monitoring Blood Glucose
- T1DM: Type 1 Diabetes Mellitus
- T2DM: Type 2 Diabetes Mellitus
Source Citation
Anne L. Peters, Andrew J. Ahmann, Tadej Battelino, Alison Evert, Irl B. Hirsch, M. Hassan Murad, William E. Winter, Howard Wolpert, Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 101, Issue 11, 1 November 2016, Pages 3922–3937, https://doi.org/10.1210/jc.2016-2534
Disclaimer
Codes
CPT Codes
Code | Descriptor |
---|---|
96170 | Health behavior intervention, family (without the patient present), face-to-face; initial 30 minutes |
96167 | Health behavior intervention, family (with the patient present), face-to-face; initial 30 minutes |
96156 | Health behavior assessment, or re-assessment (ie, health-focused clinical interview, behavioral observations, clinical decision making) |
98962 | Education and training for patient self-management by a qualified |
98961 | Education and training for patient self-management by a qualified |
96158 | Health behavior intervention, individual, face-to-face; initial 30 minutes |
99078 | Physician or other qualified health care professional qualified by education |
96159 | Health behavior intervention, individual, face-to-face; each additional 15 minutes (List separately in addition to code for primary service) |
98960 | Education and training for patient self-management by a qualified |
0592T | Health and well-being coaching face-to-face; individual |
96164 | Health behavior intervention, group (2 or more patients), face-to-face; initial 30 minutes |
96168 | Health behavior intervention, family (with the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service) |
0593T | Health and well-being coaching face-to-face; group (2 or more individuals) |
96165 | Health behavior intervention, group (2 or more patients), face-to-face; each additional 15 minutes (List separately in addition to code for primary service) |
0591T | Health and well-being coaching face-to-face; individual |
ICD-10 Codes
Code | Descriptor | Documentation Concepts | Quality/Performance |
---|---|---|---|
E10.9 | Type 1 diabetes mellitus without complications | Type, caused by due to, complications or manifestations, laterality | |
E09.3522 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3492 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E11.59 | Type 2 diabetes mellitus with other circulatory complications | Type, caused by due to, complications or manifestations, laterality | |
E09.39 | Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication | Type, caused by due to, complications or manifestations, laterality | |
E13.621 | Other specified diabetes mellitus with foot ulcer | Type, caused by due to, complications or manifestations, laterality | |
E10.3312 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.628 | Type 1 diabetes mellitus with other skin complications | Type, caused by due to, complications or manifestations, laterality | |
E11.628 | Type 2 diabetes mellitus with other skin complications | Type, caused by due to, complications or manifestations, laterality | |
E11.3532 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.43 | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy | Type, caused by due to, complications or manifestations, laterality | |
E11.3549 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E10.311 | Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema | Type, caused by due to, complications or manifestations, laterality | |
E11.311 | Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema | Type, caused by due to, complications or manifestations, laterality | |
E13.3412 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3553 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E11.22 | Type 2 diabetes mellitus with diabetic chronic kidney disease | Type, caused by due to, complications or manifestations, laterality | |
E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy | Type, caused by due to, complications or manifestations, laterality | |
E13.37X2 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3559 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3512 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3543 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.3392 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3541 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.59 | Diabetes mellitus due to underlying condition with other circulatory complications | Type, caused by due to, complications or manifestations, laterality | |
E10.39 | Type 1 diabetes mellitus with other diabetic ophthalmic complication | Type, caused by due to, complications or manifestations, laterality | |
E08.3532 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.29 | Other specified diabetes mellitus with other diabetic kidney complication | Type, caused by due to, complications or manifestations, laterality | |
E09.3312 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E11.43 | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy | Type, caused by due to, complications or manifestations, laterality | |
E10.3522 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3492 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.44 | Other specified diabetes mellitus with diabetic amyotrophy | Type, caused by due to, complications or manifestations, laterality | |
E10.3559 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3512 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3543 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E11.3292 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.0 | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) | Type, complications/manifestations, due to/caused by, temporal factors | RXHCC30, HCC17 |
E10.649 | Type 1 diabetes mellitus with hypoglycemia without coma | Type, caused by due to, complications or manifestations, laterality | |
E11.649 | Type 2 diabetes mellitus with hypoglycemia without coma | Type, caused by due to, complications or manifestations, laterality | |
E08.3549 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.22 | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease | Type, caused by due to, complications or manifestations, laterality | |
E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy | Type, caused by due to, complications or manifestations, laterality | |
E11.3553 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.52 | Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene | Type, caused by due to, complications or manifestations, laterality | |
E11.3552 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye | Type, caused by due to, complications or manifestations, laterality | |
E09.37X1 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3519 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E10.43 | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy | Type, caused by due to, complications or manifestations, laterality | |
E09.3411 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E11.39 | Type 2 diabetes mellitus with other diabetic ophthalmic complication | Type, caused by due to, complications or manifestations, laterality | |
E09.59 | Drug or chemical induced diabetes mellitus with other circulatory complications | Type, caused by due to, complications or manifestations, laterality | |
E13.641 | Other specified diabetes mellitus with hypoglycemia with coma | Type, caused by due to, complications or manifestations, laterality | |
E08.610 | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy | Type, caused by due to, complications or manifestations, laterality | |
E09.610 | Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy | Type, caused by due to, complications or manifestations, laterality | |
E11.3293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.1 | Other specified diabetes mellitus with hyperosmolarity with coma | Type, complications/manifestations, due to/caused by, temporal factors | RXHCC30, HCC17 |
E11.3513 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E09.3542 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3391 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3299 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3319 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3521 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.69 | Other specified diabetes mellitus with other specified complication | Type, caused by due to, complications or manifestations, laterality | |
E09.3539 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3493 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E10.3523 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E11.3211 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3599 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy | Type, caused by due to, complications or manifestations, laterality | |
E09.22 | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease | Type, caused by due to, complications or manifestations, laterality | |
E11.3591 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3219 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3313 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E11.3529 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3499 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3533 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E09.3299 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3393 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.3513 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E10.3542 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3391 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3411 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.37X3 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E09.43 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy | Type, caused by due to, complications or manifestations, laterality | |
E13.3413 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.3552 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.39 | Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication | Type, caused by due to, complications or manifestations, laterality | |
E10.59 | Type 1 diabetes mellitus with other circulatory complications | Type, caused by due to, complications or manifestations, laterality | |
E10.37X1 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.319 | Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema | Type, caused by due to, complications or manifestations, laterality | |
E13.49 | Other specified diabetes mellitus with other diabetic neurological complication | Type, caused by due to, complications or manifestations, laterality | |
E09.3519 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy | Type, caused by due to, complications or manifestations, laterality | |
E10.22 | Type 1 diabetes mellitus with diabetic chronic kidney disease | Type, caused by due to, complications or manifestations, laterality | |
E08.3529 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3311 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3499 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3533 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.3591 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.65 | Other specified diabetes mellitus with hyperglycemia | Type, caused by due to, complications or manifestations, laterality | |
E10.3313 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.620 | Other specified diabetes mellitus with diabetic dermatitis | Type, caused by due to, complications or manifestations, laterality | |
E10.3539 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3493 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E09.3523 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3491 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.630 | Diabetes mellitus due to underlying condition with periodontal disease | Type, caused by due to, complications or manifestations, laterality | |
E11.3319 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E09.630 | Drug or chemical induced diabetes mellitus with periodontal disease | Type, caused by due to, complications or manifestations, laterality | |
E10.8 | Type 1 diabetes mellitus with unspecified complications | Type, caused by due to, complications or manifestations, laterality | |
E11.3312 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3532 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.622 | Type 1 diabetes mellitus with other skin ulcer | Type, caused by due to, complications or manifestations, laterality | |
E11.622 | Type 2 diabetes mellitus with other skin ulcer | Type, caused by due to, complications or manifestations, laterality | |
E08.49 | Diabetes mellitus due to underlying condition with other diabetic neurological complication | Type, caused by due to, complications or manifestations, laterality | |
E10.29 | Type 1 diabetes mellitus with other diabetic kidney complication | Type, caused by due to, complications or manifestations, laterality | |
E08.3522 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.39 | Other specified diabetes mellitus with other diabetic ophthalmic complication | Type, caused by due to, complications or manifestations, laterality | |
E11.3492 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3559 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E10.52 | Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene | Type, caused by due to, complications or manifestations, laterality | |
E11.3543 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy | Type, caused by due to, complications or manifestations, laterality | |
E09.3512 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3549 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3553 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E10.44 | Type 1 diabetes mellitus with diabetic amyotrophy | Type, caused by due to, complications or manifestations, laterality | |
E09.3292 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.618 | Type 1 diabetes mellitus with other diabetic arthropathy | Type, caused by due to, complications or manifestations, laterality | |
E11.618 | Type 2 diabetes mellitus with other diabetic arthropathy | Type, caused by due to, complications or manifestations, laterality | |
E11.69 | Type 2 diabetes mellitus with other specified complication | Type, caused by due to, complications or manifestations, laterality | |
E11.3522 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3492 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E11.49 | Type 2 diabetes mellitus with other diabetic neurological complication | Type, caused by due to, complications or manifestations, laterality | |
E09.29 | Drug or chemical induced diabetes mellitus with other diabetic kidney complication | Type, caused by due to, complications or manifestations, laterality | |
E13.3212 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E10.638 | Type 1 diabetes mellitus with other oral complications | Type, caused by due to, complications or manifestations, laterality | |
E11.638 | Type 2 diabetes mellitus with other oral complications | Type, caused by due to, complications or manifestations, laterality | |
E09.3532 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3592 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.621 | Diabetes mellitus due to underlying condition with foot ulcer | Type, caused by due to, complications or manifestations, laterality | |
E09.621 | Drug or chemical induced diabetes mellitus with foot ulcer | Type, caused by due to, complications or manifestations, laterality | |
E10.3292 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3551 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.9 | Diabetes mellitus due to underlying condition without complications | Type, caused by due to, complications or manifestations, laterality | |
E09.44 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy | Type, caused by due to, complications or manifestations, laterality | |
E09.3549 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.69 | Diabetes mellitus due to underlying condition with other specified complication | Type, caused by due to, complications or manifestations, laterality | |
E10.3553 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E09.52 | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene | Type, caused by due to, complications or manifestations, laterality | |
E11.3559 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.65 | Type 2 diabetes mellitus with hyperglycemia | Type, caused by due to, complications or manifestations, laterality | |
E08.3543 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E10.3512 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3542 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.29 | Diabetes mellitus due to underlying condition with other diabetic kidney complication | Type, caused by due to, complications or manifestations, laterality | |
E10.49 | Type 1 diabetes mellitus with other diabetic neurological complication | Type, caused by due to, complications or manifestations, laterality | |
E10.3513 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.59 | Other specified diabetes mellitus with other circulatory complications | Type, caused by due to, complications or manifestations, laterality | |
E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3299 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3511 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.37X1 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.319 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema | Type, caused by due to, complications or manifestations, laterality | |
E09.319 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema | Type, caused by due to, complications or manifestations, laterality | |
E10.3552 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3519 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3291 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.8 | Diabetes mellitus due to underlying condition with unspecified complications | Type, caused by due to, complications or manifestations, laterality | |
E10.3293 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E11.101 | Type 2 diabetes mellitus with hyperosmolarity with coma | Type, complications/manifestations, due to/caused by, temporal factors | RXHCC30, HCC17 |
E08.44 | Diabetes mellitus due to underlying condition with diabetic amyotrophy | Type, caused by due to, complications or manifestations, laterality | |
E08.620 | Diabetes mellitus due to underlying condition with diabetic dermatitis | Type, caused by due to, complications or manifestations, laterality | |
E10.3591 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E09.620 | Drug or chemical induced diabetes mellitus with diabetic dermatitis | Type, caused by due to, complications or manifestations, laterality | |
E09.69 | Drug or chemical induced diabetes mellitus with other specified complication | Type, caused by due to, complications or manifestations, laterality | |
E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E10.3529 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3593 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E09.3499 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3533 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E10.65 | Type 1 diabetes mellitus with hyperglycemia | Type, caused by due to, complications or manifestations, laterality | |
E09.3319 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.630 | Other specified diabetes mellitus with periodontal disease | Type, caused by due to, complications or manifestations, laterality | |
E13.3213 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.52 | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene | Type, caused by due to, complications or manifestations, laterality | |
E08.3539 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3493 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.22 | Other specified diabetes mellitus with diabetic chronic kidney disease | Type, caused by due to, complications or manifestations, laterality | |
E11.3523 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E10.3211 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E13.3399 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E13.610 | Other specified diabetes mellitus with diabetic neuropathic arthropathy | Type, caused by due to, complications or manifestations, laterality | |
E11.3411 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E08.641 | Diabetes mellitus due to underlying condition with hypoglycemia with coma | Type, caused by due to, complications or manifestations, laterality | |
E09.641 | Drug or chemical induced diabetes mellitus with hypoglycemia with coma | Type, caused by due to, complications or manifestations, laterality | |
E09.3293 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E11.37X1 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye | Type, caused by due to, complications or manifestations, laterality | |
E09.3552 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3519 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E08.3299 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.29 | Type 2 diabetes mellitus with other diabetic kidney complication | Type, caused by due to, complications or manifestations, laterality | |
E09.49 | Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication | Type, caused by due to, complications or manifestations, laterality | |
E13.37X9 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3542 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye | Type, caused by due to, complications or manifestations, laterality | |
E13.43 | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy | Type, caused by due to, complications or manifestations, laterality | |
E09.3513 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E13.3419 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3391 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E09.65 | Drug or chemical induced diabetes mellitus with hyperglycemia | Type, caused by due to, complications or manifestations, laterality | |
E11.3539 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.3493 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E08.3523 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality | |
E09.3211 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye | Type, caused by due to, complications or manifestations, laterality | |
E11.52 | Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene | Type, caused by due to, complications or manifestations, laterality | |
E10.3319 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E11.44 | Type 2 diabetes mellitus with diabetic amyotrophy | Type, caused by due to, complications or manifestations, laterality | |
E09.3529 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E10.3499 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye | Type, caused by due to, complications or manifestations, laterality | |
E10.69 | Type 1 diabetes mellitus with other specified complication | Type, caused by due to, complications or manifestations, laterality | |
E10.3533 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral | Type, caused by due to, complications or manifestations, laterality |